MYDA Advisors’s Heron Therapeutics HRTX Stock Holding History

MYDA Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,109	Closed	-$354K	–	155
2018 Q2	$354K	Buy	+9,109	New	+$290K	0.15%	109

Other funds holding HRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MYDA Advisors's HRTX Position: Q3 2018 in Review

MYDA Advisors sold out of Heron Therapeutics (HRTX) in Q3 2018, closing a stake of 9,109 shares — an estimated $354K sold.

MYDA Advisors first reported a position in HRTX in Q2 2018 and held it in 1 quarter. The position peaked at $354K in Q2 2018. 194 funds tracked by Wall St. Rank hold HRTX as of Q3 2018.

MYDA Advisors reported no remaining Heron Therapeutics position as of Q3 2018 after selling out during the quarter.
MYDA Advisors sold 9,109 Heron Therapeutics shares in Q3 2018, an estimated $354K.
MYDA Advisors first reported a position in Heron Therapeutics in Q2 2018 and held it in 1 quarter.
MYDA Advisors's Heron Therapeutics position peaked at $354K in Q2 2018.
194 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2018.

Based on MYDA Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.